UK 356618

CAT: 0804-HY-107394-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-107394-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC50 of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3[1].
CAS Number
[230961-08-7]
UNSPSC
12352005
Hazard Statement
H302
Target
MMP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/uk-356618.html
Purity
98.91
Solubility
DMSO : 25 mg/mL (ultrasonic; adjust pH to 2 with 1M HCl)
Smiles
CC1=C(C2=CC=CC=C2)C=CC(CCC[C@H](CC(NO)=O)C(N[C@@H](C(C)(C)C)C(N[C@@H](C3=CC=CC=C3)C)=O)=O)=C1
Molecular Formula
C34H43N3O4
Molecular Weight
557.72
Precautions
H302
References & Citations
[1]Fray MJ, et al. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1) . Bioorg Med Chem Lett. 2001 Feb 26;11 (4) :571-4.|[2]Yan HQ, et al. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget. 2016 Sep 20;7 (38) :62070-62083.|[3]Hafez S, et al. Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke. 2016 Mar;47 (3) :843-51.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-1; MMP-13; MMP-14; MMP-2; MMP-3; MMP-9

Popular Products